June 24, 2020 / 7:58 PM / 2 months ago

BRIEF-AstraZeneca Says PT010 Significantly Reduced Rate Of Moderate Or Severe COPD Exacerbations In Phase III Ethos Trial

June 24 (Reuters) - AstraZeneca PLC:

* PT010 SIGNIFICANTLY REDUCED RATE OF MODERATE OR SEVERE COPD EXACERBATIONS IN PHASE III ETHOS TRIAL

* ASTRAZENECA - PT010 SHOWED STATISTICALLY SIGNIFICANT REDUCTION IN RATE OF MODERATE/SEVERE EXACERBATIONS IN PATIENTS WITH MODERATE TO VERY SEVERE COPD

* ASTRAZENECA - COMPARED WITH GLYCOPYRRONIUM/FORMOTEROL FUMARATE, PT010 ACHIEVED 24% REDUCTION IN EXACERBATIONS

* ASTRAZENECA - PT010 ACHIEVED 13% REDUCTION (P=0.003) COMPARED WITH PT009 (BUDESONIDE/FORMOTEROL FUMARATE)

* ASTRAZENECA - IN KEY SECONDARY GOAL, PT010 SHOWED 46% REDUCTION IN RISK OF ALL-CAUSE MORTALITY COMPARED WITH GLYCOPYRRONIUM/FORMOTEROL FUMARATE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below